Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.38 |
| ▸ | FAP | Q12884 | 3/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 6/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13660642 | 0.89 | CLK1 (0.40) | IDEHPGDALDH1A1 | |
| SCHEMBL13660483 | 0.89 | DPP4 (0.37) | DPP4FAPIDEHPGDALDH1A1 | |
| SCHEMBL13660486 | 0.74 | NAMPT (0.42) | DPP4FAPDPP8DPP7HDAC2 | |
| SCHEMBL10293353 | 0.72 | HPGD (0.43) | DPP4FAPDPP8DPP7HDAC2 | |
| SCHEMBL14073993 | 0.69 | GAA (0.61) | DPP4FAPHDAC2HPGDTSHR | |
| SCHEMBL4999846 | 0.68 | GAA (0.59) | DPP4FAPHDAC2HPGDTSHR | |
| SCHEMBL13660641 | 0.67 | ALDH1A1 (0.51) | HPGDTSHRALDH1A1MAPK1CYP2C19 | |
| SCHEMBL8312865 | 0.66 | ROCK2 (0.56) | DPP4FAPHDAC2HPGDTSHR | |
| SCHEMBL4774911 | 0.66 | ROCK2 (0.56) | DPP4FAPHDAC2HPGDTSHR | |
| SCHEMBL8306650 | 0.65 | ROCK2 (0.55) | DPP4FAPHDAC2HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608627-B2 | I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20080064715-A1 | 6-Azaindole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064715-A1 | 6-Azaindole Compound | RELA, NFKBIA, GPR119 | DPP4 1227/4885FAP 4841/4885DPP8 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.